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Objective: The prevalence of depressive symptoms is high in patients with systemic sclerosis (SSc, scleroderma).
This study was conducted to determine which disease-related and psychosocial factors are associated with
depressive symptoms, independent of sociodemographic factors.
Methods: In total, 215 patients with SSc completed questionnaires on sociodemographics, physical functioning
(HAQ-DI), pain (VAS), fatigue (CIS), psychosocial characteristics (CISS, ICQ, PRQ, ASE, FoP-Q-SF) and depressive
symptoms (CES-D). Disease characteristics (disease duration, disease subtype, modiﬁed Rodnan Skin Score)
were collected. Hierarchical linear regression analyses were conducted to assess associations with depressive
symptoms.
Results: The mean CES-D score was 12.9 (SD=9.7) and the prevalence of patients scoring>= 16 and>=19
were 32.1% and 25.1%, respectively. The variance explained by sociodemographics and disease characteristics
was negligible (R2≤ .09). Fatigue and pain were independently associated with depressive symptoms
(R2 change=.35). After adding psychological factors (R2 change=.21), satisfaction with social support,
emotion-focused coping and helplessness were also signiﬁcantly associated with depressive symptoms. Higher
fear of progression was associated with more depressive symptoms (P≤ .01), and appearance self-esteem
showed a marginally signiﬁcant association (P=.08).
Conclusion: Depressive symptoms were common in the present sample of patients with SSc and were inde-
pendently associated with pain, fatigue, social support, emotion-focused coping, helplessness and fear of
progression. Results suggest that, in addition to assessment of disease characteristics, attention should be
given also to psychosocial factors found to be associated with depressive symptoms. For the development
and trialling of psychological interventions, fear of progression could be an important target.© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Psychological consequences in patients with rheumatic diseases
are increasingly recognised. Many studies focus on patients with
rheumatoid arthritis and other inﬂammatory rheumatic diseases.
Recently, the literature on psychological problems in patients with
systemic sclerosis (scleroderma, SSc) is growing [1]. However,
much is still unknown about the psychological problems of patients
with SSc and their relationship with the disease.
Systemic sclerosis is a rare connective-tissue disease, with an
estimated prevalence of 8.9 per 100,000 adults in the Netherlands
and an estimated incidence of .77 per 100,000 [2]. The disease isBox 9011, 6500 GM Nijmegen,
. Kwakkenbos).
vier OA license.characterized by thickening of the skin as a result of ﬁbrosis. Further-
more, SSc can lead to severe dysfunction and failure of almost any in-
ternal organ [3], and Raynaud's phenomenon is common. Although
there is considerable heterogeneity in SSc manifestation, it has seri-
ous consequences in many patients. SSc confers a high mortality
risk, with standardized mortality ratios of 1.5 to 7.2 [4]. The pres-
ence of anti–topoisomerase I antibodies and internal organ involve-
ment are important determinants of mortality [4]. No effective
treatments are available yet, and existing treatments mainly focus
on symptom reduction.
As a consequence of the disease, patients with SSc report impair-
ments in their physical as well as mental health-related quality of
life [5]. Fatigue and pain are often reported by patients with SSc
[6,7] and SSc causes increased disability over time [8]. Elevated levels
of depressive symptomswere observed in 35-65% of the patients with
SSc [9].
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threatening disease. Fear of progression of the disease (FoP) is often
reported as a major concern for patients with SSc and is related to
mental health in diverse medical conditions [6,7,10–13]. However,
there are no studies examining the relationship of FoP and psycho-
logical distress in SSc.
SSc also differs from other rheumatic diseases in terms of the
changes in appearance it may cause. Most affected parts are the face
and hands [14]. Previous studies of body image satisfaction and
appearance self-esteem (ASE) in patients with SSc suggest that
changes in the hands, ﬁngers and face are most relevant in pre-
dicting overall ASE [15,16]. Low appearance self-esteem is related
to psychological variables [15–17], and it is suggested that ASE is
a mediator of the relationship between skin thickening and psy-
chological distress [16].
As of now, it is hard to come to a conclusion as to which factors are
of importance and could be targeted in treating depressive symptoms
in SSc patients. Previous studies examining variables related to de-
pressive symptoms revealed varying results [18–22]. This is to some
extent due to the fact that different concepts were included. Some
studies report that SSc severity or physical functioning are associates
of depressive symptoms [19,20], but this ﬁnding was not always rep-
licated in other studies [18,21]. Some studies [18,21,22] included
physical as well as psychological measures e.g., aspects of personality
[18,22], adequacy of emotional or social support [18,21], and accep-
tance, and found these [21] to be independently associated with de-
pressive symptoms. None of the previous studies included fear of
progression and appearance self-esteem, which are both often
found as highly distressing to patients with SSc [6,7,11,17].
For a more systematic approach, this study was conducted to de-
termine the independent association of sociodemographic variables,
health status and psychological variables with depressive symptoms,
as was recommended in the review of depression in SSc by Thombs et
al. [9]. Factors included were derived from literature on associates of
depression as well as factors patients reported as distressing in previ-
ous studies (appearance self-esteem, fear of progression). Examining
all these variables in one model might provide us with starting points
for developing (interdisciplinary) interventions for patients with SSc
and symptoms of depression.
Method
Patients and procedure
Data were collected in the baseline assessment of the cohort study
“Psychological factors in scleroderma,” including patients with a de-
ﬁnitive diagnosis of SSc according to the preliminary ARA classiﬁca-
tion criteria [23] under treatment in the Sint Maartenskliniek or
Radboud University Medical Center Nijmegen, the Netherlands. The
main objective of the cohort study is to determine which psychological
variables (e.g., coping, cognitions, social support) predict psychological
distress. Patients in the cohort study complete sets of physical and psy-
chological questionnaires every 6 months over 3 years. Furthermore, a
number of disease characteristics were assessed by a rheumatologist
(e.g., modiﬁed Rodnan Skin Score (mRSS). Exclusion criteria for partic-
ipation in the cohort were a life expectancy of less than a year (because
of the burden of the study), acute serious complications (e.g., acute
renal crisis), severe psychiatric comorbidity (e.g., severe substance
abuse, psychosis or dementia), other serious comorbidities (e.g., can-
cer) and insufﬁcient knowledge of the Dutch language. The attending
rheumatologist assessed whether a patient met one or more of the ex-
clusion criteria based on clinical experience, using a checklist stat-
ing the exclusion criteria. Data on the reasons for exclusion for
individual patients are not available. All eligible patients in both clinics
were invited to participate in the study by their attending rheumatol-
ogist. After they read the written patient information, they had theopportunity to ask questions to their rheumatologist or the researcher.
Informed consent was obtained before the patients completed their
ﬁrst questionnaire at home. The study was approved by the local med-
ical ethical board (CMO 2008/109). In total, 279 patients were invit-
ed to participate, of whom 215 completed the baseline questionnaire
(response rate 77.1%). Non-responders did not differ from responders




The sociodemographic variables assessed were: age, sex, marital
status, education and current employment status.
Disease characteristics
The attending rheumatologist assessed disease duration (time
since onset of ﬁrst non-Raynaud's symptoms), SSc disease subtype
(limited or diffuse), and mRSS. Furthermore, auto-antibodies (ANA,
ACA, Anti-TOPO, Anti-RNP) were assessed to describe our sample.
Physical functioning
Patients completed the Dutch version of the Scleroderma Health
Assessment Questionnaire (SHAQ). The SHAQ consists of the Health
Assessment Questionnaire (HAQ) and Visual Analogue Scales mea-
suring perceived severity of six disease symptoms. The Disability
Index score consists of 20 items, measuring 8 dimensions of function-
ing (dressing and grooming, ability to get up, eating, walking, person-
al hygiene, reach, grip strength and activities). The score of each
dimension ranges from 0 (best function) to 3 (worst function), and
the mean of these scores can be calculated as an indicator of overall
physical functioning (HAQ-DI) with higher scores depicting worse
functioning. The HAQ was originally developed for use in rheumatoid
arthritis [24] but has demonstrated good reliability and validity in pa-
tients with SSc [25].
Pain was assessed using a Visual Analogue Scale (VAS) of 10 cm,
ranging from 0 (no pain) to 100 (severe pain).
Fatigue was assessed with the “subjective experience of fatigue”
subscale of the Checklist Individual Strength [26]. This subscale con-
sists of 8 items, scored on a 7-point Likert scale. Higher scores depict
higher levels of fatigue. The CIS has shown to be valid and reliable
across different settings [26].
Depressive mood
The Center for Epidemiologic Studies- Depression Scale (CES-D)
was used to assess depressive mood. The CES-D was originally devel-
oped to measure depressive symptomatology in the general popula-
tion [27]. Recently, the scale has shown to be a reliable and valid
measure of depressive symptoms in patients with SSc [28]. The
CES-D is a 20-item measure, with the frequency of each depressive
symptom rated on a 4-point Likert scale ranging from 0 to 3 (“rarely
or none of the time” to “most or all of the time”). A score of ≥16 on
the CES-D is considered as the cut-off for possible depression [27],
while the cut-off ≥19 is identiﬁed as the most accurate cut-off for
identifying major depression in arthritis [29].
Social support was measured using the Personal Resources
Questionnaire 85-Part2 (PRQ85) [30]. Part 2 of the PRQ85 consists
of 25 items measuring the patient's perceived level of social support.
Items are scored on a 7-point Likert scale, ranging from 1 (strongly
disagree) to 7 (strongly agree). Higher scores on the PRQ85 depict
greater availability of and satisfaction with social support. The ques-
tionnaire has shown to be reliable and valid in healthy adults [31].
Furthermore, some support for the validity of the PRQ85 in patients
with SSc was provided by Moser et al. [32].
Coping strategies were assessed using the Coping Inventory Stress-
ful Situations (CISS) [33]. The CISS consists of 48 items, measuring
Table 1
Sociodemographic variables (N=215), disease variables, study variables, and univari-
ate associations with depressive symptoms (CES-D, range 0–60).
Variables Value Correlationa P
Demographic
Gender (% female) 146 (67.9%) −.17 .01




Higher education (>12 yrs) 87 (41.2%) −.05 .51
Currently employed 70 (32.6%) −.10 .13
Married/ cohabitating 162 (75.4%) −.16 .02
Disease characteristics





Patients with limited SSc 158 (74.9%) .02 .74
Mean mRSS 6.4 (SD=5.9,
range 0–37)
.06 .36
ANA positive 196 (91.2%)
ACA positive 54 (25.1%)
Anti-TOPO positive 57 (26.6%)
Anti-RNP positive 14 (6.5%)
Physical functioning
HAQ-DI (0–3) 1.04 (SD=.74) .35 b.01
Pain visual analogue scale (0–100) 28.6 (SD=24.5) .37 b.01
Fatigue (CIS) (7–56) 36.2 (SD=12.6) .62 b.01
Psychosocial factors
Social support (PRQ)(25–175) 131.5 (SD=20.2) −.36 b.01
Helplessness (ICQ)(6–24) 12.7 (SD=4.3) .59 b.01
Acceptance (ICQ)(6–24) 16.4 (SD=4.1) −.43 b.01
Problem-focused coping (CISS)(16–80) 50.6 (SD=11.0) .02 .81
Emotion-focused coping (CISS)(16–80) 34.0 (SD=11.7) .49 b.01
Avoidance coping (CISS)(16–80) 40.4 (SD=9.9) .10 .13
Appearance self esteem (ASE)(6–30) 19.6 (SD=4.1) −.43 b.01
Fear of progression (FoP-Q-SF)(1–60) 30.0 (SD=9.0) .58 b.01
mRSS, modiﬁed Rodnan Skin Score; ANA, antinuclear antibody; ACA, anticentromere
antibody; anti-TOPO, antitopomerase antibody; anti-RNP, antiribonuclear protein anti-
bodies.
a Pearson correlations for continuous variables, point-biserial correlations for dichoto-
mous variables.
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coping and avoidance. Items are scored on a 5-point Likert scale, rang-
ing from 1 (not at all) to 5 (verymuch). The CISS showed good psycho-
metric properties in diverse samples [33,34].
Disease cognitions weremeasured using the Illness Cognition Ques-
tionnaire (ICQ) [34]. The ICQ consist of 18 items, measuring helpless-
ness, acceptance and disease beneﬁts. Participants rate their
agreement with the statements on a 4-point Likert scale, ranging from
1 (not at all) to 4 (completely). Higher scores on subscales reﬂect higher
levels of agreement with that particular illness cognition. The scale has
excellent construct and internal validity in chronic diseases [35]. In this
study we only used the subscales acceptance and helplessness.
Satisfactionwith appearancewasmeasured using the 6-item subscale
‘Appearance self-esteem’ of the State Self Esteem Scale [36]. The items are
scored from1 (not at all) to 5 (extremely). Higher scores depictmore sat-
isfactionwith appearance. A previous study in patientswith SSc using this
questionnaire demonstrated good internal consistency reliability [16].
Fear of progression was measured using the Short Form of the Fear
of Progression Questionnaire (FoP-Q) [12]. The FoP-Qwas developed to
measure the fear of disease progression in patients with chronic ill-
nesses. The original questionnaire comprises 43 items. The Short
Form is a 12-item measure based on the FoP-Q. Each item is scored
from 1 (never) to 5 (very often). The reliability and validity of the
FoP-Q-SF in patients with breast cancer appears to be good [13]. As
far as we know, this questionnaire was not previously used in patients
with SSc. Higher scores depict more fear of progression.
All questionnaires showed good internal consistency in our sam-
ple, Cronbach's α ranging from .77–.92.
Statistical analysis
Descriptive statistics are provided as means and standard deviations
(SD) for continuous variables and percentages for categorical variables.
Univariate associations of all sociodemographic and study variables with
depressive symptoms were calculated. Hierarchical multiple regression
analyses were conducted to determine the associations of the disease-
related stressors with depressive mood. CES-D scores were used as the
dependent variable. The independent variables were entered in the re-
gression equation in ﬁve steps. Following the model of Thombs et al.
[20], step 1 contained demographics (age, sex) and step 2 contained so-
cioeconomic status (education,married/cohabiting). In step three, disease
characteristics were added (limited/diffuse disease, disease duration,
mRSS). Step 4 consisted of physical functioning variables (HAQ,
pain, fatigue). In the ﬁfth step, psychological variables were added
(disease cognitions, social support, coping, appearance self-esteem,
fear of progression). We chose to include all psychological variables to-
gether in one step, as there is no consensus on the order of coping and
cognitions [37,38]. Given the fact that fatigue is an important character-
istic of depression, and the relatively high correlation of fatigue with
depressive symptoms, as a sensitivity analysis (to examine the ro-
bustness of our ﬁndings), step 4 and 5 were repeated omitting fatigue.
The assumption for the regression analysis (normal distribution of
residuals) was tested using a normal probability plot. There were no
indications of violation of this assumption. Furthermore, correlations
between independent variables and tolerances were calculated to
check for multicollinearity. All tolerance values were between .36
and .92, and all correlations were b=.58, indicating multicollinearity
was not an issue [39]. All statistical analyses were conducted using
Stata/IC 10.1 software (StataCorp LP, College Station, TX).
Results
Participants
In total, 69 men and 146 women completed the baseline questionnaires. Most
patients (74.1%) were married or cohabitating. Sociodemographic and disease charac-
teristics are displayed in Table 1. The mean depression score was 12.9 (SD 9.7) and theprevalence of patients scoring ≥16 in our sample was 32.1%. The prevalence of proba-
ble depression (CES-D≥19) was 25.1%.Hierarchical regression analysis
Table 2 shows the results from the hierarchical multiple regression analysis. In
step 1 to 3, the variance explained was negligible (R2≤ .09). Sex and marital status
were signiﬁcantly associated with depressive symptoms. Of the disease characteris-
tics (disease type, disease duration, mRSS) added in step 3, only mRSS showed a bor-
derline signiﬁcant association with depressive symptoms (P=.09). Of the physical
function measures added in step 4, fatigue and pain were signiﬁcant correlates, while
HAQ score was not. Patients who experienced more fatigue or pain, reported more
depressive symptoms (Pb .01 and P=.03, respectively). After adding these physical
functioning measures, sex was no longer signiﬁcantly associated with depressive symp-
toms. The amount of variance explained increased remarkably (+35%) in step 4. Psy-
chological factors were added in step 5. In this ﬁnal model, signiﬁcant correlates were
pain (P=.05), fatigue (Pb .01), social support (P=.01), emotion-focused coping
(Pb .01), helplessness (P=.03) and fear of progression (Pb .01). The total explained
amount of variance in depressive symptoms was 64.7%. Patients who were more satis-
ﬁed with their social network reported less depressive symptoms, while patients using
emotion-focused coping as an important strategy, had higher depression scores. Feelings
of helplessness were associated with more depressive symptoms. Higher fear of progres-
sion was associated with more depressive symptoms. The p-value of appearance self-
esteem indicated a trend (P=.08), suggesting that patients with higher appearance
self-esteem reported less depressive symptoms.
The sensitivity analysis omitting fatigue revealed highly similar results (not
shown). Differences with the original model were, that in step 4 (adding HAQ-DI and
pain), the HAQ-DI was now signiﬁcantly associated with depressive symptoms
(B=2.38, P=.03), and R2 was substantially lower (R2=.21). In the ﬁnal model, the
only difference was the signiﬁcance level of appearance self-esteem (B=−.37,
Table 2
Hierarchical regression analyses of demographics, disease status and psychological variables associated with depressive symptoms (CES-D, range 0–60).
Variable B [95% CI] P Beta Total R2
Step 1) Demographics Age −.05 [−.16,.05] .33 −.07
Sex −3.35 [−3.00,1.28] .02 −.16 .03⁎
Step 2) Socioeconomic status Age −.07 [−.19,.04] .21 −.09
Male sex −3.06 [−5.84, −.27] .03 −.15
Higher education −.1.42 [−4.18,1.35] .31 −.07
Married/Cohabitating −3.92 [−6.97, −.88] .01 −.17 .07
Step 3) Disease characteristics Age −.08 [−.21,.04] .20 −.10
Male sex −3.95 [−6.93, −.97] .01 −.19
Higher education −1.41 [−4.32,1.50] .34 −.07
Married/Cohabitating −3.76 [−7.00, −.52] .02 −.16
Limited disease −.95 [−4.40,2.50] .59 −.04
Disease duration .04 [−.13,.21] .64 .03
mRSS .22 [−.03,.47] .09 .13 .09
Step 4) Physical functioning Age −.08 [.18,.02] .13 −.09
Male sex −1.42 [−3.89,1.06] .26 −.07
Higher education −.92 [−3.30,1.45] .44 −.04
Married/Cohabitating −2.48 [−5.08,.12] .06 −.11
Limited disease .87 [−1.93,3.67] .54 .04
Disease duration .03 [−.11,.17] .71 .02
mRSS .11 [−.10,.32] .32 .07
HAQ score −.52 [−2.45,1.41] .60 −.04
Pain .06 [.01,.12] .03 .15
Fatigue .44 [.34,.54] b.01 .56 .44⁎⁎
Step 5) Psychosocial factorsa Age −.04 [−.12,.05] .37 −.05
Male sex −.86 [−3.00,1.28] .43 −.04
Higher education −.37 [−2.42,1.69] .73 −.02
Married/Cohabitating −2.0 [−4.41,.43] .11 −.09
Limited disease −.04 [−2.38,2.31] .98 .00
Disease duration .02 [−.10,.14] .74 .02
mRSS .08 [−.10,.26] .41 .05
HAQ score −1.16 [−2.95,.62] .20 −.09
Pain .05 [.00,.09] .05 .11
Fatigue .23 [.13,.33] b.01 .31
Social support −.03 [−.12, −.01] .01 −.14
Helplessness .39 [.04,.75] .03 .17
Acceptance .06 [−.26,.37] .69 .03
Problem-focused coping −.03 [−.12,.07] .62 −.03
Emotion-focused coping .18 [.08,.28] b.01 .23
Avoidance coping .06 [−.05,.16] .30 .06
Appearance self esteem −.23 [−.49,.03] .08 −.10
Fear of progression .20 [.05,.34] b.01 .18 .65⁎⁎
a Final model.
⁎ P-value for the change in variance accounted for (ΔR2 )≤ .05.
⁎⁎ P-value for the change in variance accounted for (ΔR2 )≤ .001.
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model (R2=.60).Discussion
This study assessed the independent association of sociodemo-
graphic, disease, and psychosocial variables, including appearance
self-esteem and fear of progression, with depressive symptoms. De-
pressive symptoms were prevalent in our sample, comparable to
those in previous studies [21,28], as was the percentage of patients
scoring above the cut-offs for possible and probable depression
(32.1% and 25.1%, respectively) [9].
Signiﬁcant correlates of depressive symptomswere found, in addition
to pain and fatigue, mostly in the psychological domain. Depressive
symptoms were associated with lower satisfaction with social support,
emotion-focused coping, helplessness and higher fear of progression.
The variance explained by the sociodemographic measures and disease
characteristics assessed in the present study was negligible. Therefore, it
is recommended that, in addition to assessment of physical functioning,
attention should be paid to pain, fatigue and psychological factors found
to be associated with depressive symptoms. A recent study of patients
with rheumatoid arthritis showed that long-term patterns of depression
are associated with worse function and perceptions of poor health [40].
Appropriate and timely treatment of depressive symptoms mighttherefore contribute to an improvement in health outcomes, also for pa-
tients with SSc.
To our knowledge, this is the ﬁrst study that included appearance
self-esteem and fear of progression as correlates of depression, in addi-
tion to sociodemographics, disease characteristics and physical func-
tioning. Body image concerns as well as fear of the future were
identiﬁed as important psychological stressors in patients with SSc in
many existing studies [6,7,10,11]. Moreover, the present study suggests
they both are independently associated with depressive symptoms, al-
though the association of appearance self-esteem with depressive
symptoms should be interpretedwith caution since it was onlymargin-
ally signiﬁcant. More research is needed to conﬁrm our ﬁndings on ap-
pearance self-esteem.
An important ﬁnding from this study was that fear of progres-
sion is associated with depression. Because SSc is a serious and po-
tentially life-threatening disease, disease progression is a real
concern for most patients. However, although fear of progression
may have some basis in reality, patients could overestimate
their fear of progression in comparison to the likelihood of actu-
al progression. Decreasing this dysfunctional fear to a more func-
tional level might lead to fewer depressive symptoms and an
increased quality of life. A recent study showed that two short
psychotherapeutic group interventions in cancer patients were ef-
fective in reducing fear of progression in the long term [41]. The authors
also found signiﬁcant improvements in depression, anxiety and health-
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showed a higher association with depressive symptoms than actual in-
dicators of the likelihood of progression (disease type, disease duration,
mRSS), this could be an important target of intervention in patients
with SSc aswell. As of now, it is not clear whether this ﬁnding is unique
for patients with SSc, or if it is also true for patients with other chronic
diseases (like rheumatoid arthritis), for which fear of progression
might play an important role as well.
Ideally, psychological interventions for depressive symptoms in
SSc should be integrated into interdisciplinary care, taking levels of
fatigue and pain into account. Solving sleep problems or changing
unhelpful coping behaviour could help patients decrease fatigue
levels. In addition, exercises matched to patients' physical abilities
could help increase physical condition and reduce fatigue.
Since this study was cross-sectional, no causal relationships could
be established. Longitudinal research is needed to identify which fac-
tors predict the development of depressive symptoms over time. This
study could however be a starting point in determining which vari-
ables to include in longitudinal studies. Another limitation is that
not all possible physical consequences of SSc were included in the
present study. For example, the involvement of speciﬁc organs
was not taken into account. Furthermore, the use of self-report mea-
sures is a limitation of this study. Beyond the lack of validation
studies concerning Dutch versions of the instruments used (including
the CES-D), in SSc, method overlap can inﬂate associations between de-
pression scores and other self-report measures. Patients with depres-
sive symptoms might respond to the other self-report measures in a
more negative manner as well. Another limitation of the use of self-
report measurements in this study is that the association of helpless-
ness and fatigue with depressive symptoms could partly be
explained by the fact that both are an important characteristic of de-
pression. Helplessness as used in this study is a cognitive concept, and
therefore might have overlapped with the learned helplessness in de-
pression. A recent study by Thombs et al. [42] showed that, although
patients with SSc had inﬂated scores on the somatic items of the CES-
D compared to matched controls, this had no substantial impact on
the overall score of the measure. Also, the sensitivity analysis omitting
fatigue revealed only a minor difference in the variance explained in
the ﬁnal model.
Strengths of the present study were that data were collected in
a relatively large and well-deﬁned sample of patients and that a
number of physical and psychological variables were examined in
a standardized way. All variables were included in the model with-
out preselection, providing us with a precise and valid insight to
variables that are independently associated with depressive symp-
toms. The patients included in the study are comparable with the
large Dutch sample in a recent study by Vonk et al. [2] with
regard to disease characteristics and demographics, except that
our sample included slightly more men, indicating that results
are generalizable.
In conclusion, depressive symptoms were common in the present
study of patients with SSc and were independently associated with
pain, fatigue, social support, emotion-focused coping, helplessness
and fear of progression. Results suggest that, in addition to assess-
ment of disease characteristics, attention should be given also to psy-
chosocial factors found to be associated with depressive symptoms.
For the development and trialling of psychological interventions,
fear of progression could be an important target.Acknowledgements
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